Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medication Adherence | 118 | 2024 | 2187 | 13.870 |
Why?
|
Anti-HIV Agents | 140 | 2024 | 4573 | 12.520 |
Why?
|
HIV Infections | 243 | 2024 | 17569 | 11.700 |
Why?
|
Uganda | 143 | 2024 | 1361 | 6.770 |
Why?
|
Anti-Retroviral Agents | 46 | 2023 | 1789 | 5.450 |
Why?
|
Latent Tuberculosis | 6 | 2024 | 224 | 2.990 |
Why?
|
Tuberculosis | 20 | 2024 | 2029 | 2.940 |
Why?
|
Sexually Transmitted Diseases | 9 | 2024 | 668 | 2.930 |
Why?
|
Reminder Systems | 13 | 2024 | 388 | 2.850 |
Why?
|
South Africa | 34 | 2024 | 1873 | 2.360 |
Why?
|
Antiretroviral Therapy, Highly Active | 23 | 2023 | 1903 | 2.310 |
Why?
|
Qualitative Research | 30 | 2024 | 3140 | 2.250 |
Why?
|
Sexual Partners | 32 | 2024 | 805 | 2.240 |
Why?
|
Kenya | 32 | 2024 | 757 | 2.080 |
Why?
|
Rural Population | 33 | 2020 | 2325 | 1.890 |
Why?
|
Viral Load | 31 | 2024 | 3396 | 1.820 |
Why?
|
Patient Compliance | 19 | 2020 | 2697 | 1.780 |
Why?
|
HIV Seropositivity | 20 | 2022 | 966 | 1.610 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2023 | 2204 | 1.510 |
Why?
|
Social Support | 14 | 2022 | 2193 | 1.500 |
Why?
|
Social Stigma | 17 | 2022 | 788 | 1.490 |
Why?
|
Adenine | 15 | 2024 | 995 | 1.410 |
Why?
|
Truth Disclosure | 6 | 2021 | 434 | 1.360 |
Why?
|
HIV Seronegativity | 10 | 2020 | 210 | 1.340 |
Why?
|
Patient Acceptance of Health Care | 11 | 2024 | 3231 | 1.210 |
Why?
|
HIV | 12 | 2023 | 1597 | 1.210 |
Why?
|
Telemedicine | 12 | 2024 | 3109 | 1.210 |
Why?
|
Counseling | 11 | 2024 | 1554 | 1.170 |
Why?
|
Disclosure | 8 | 2022 | 755 | 1.170 |
Why?
|
Adult | 177 | 2024 | 223646 | 1.140 |
Why?
|
Family Characteristics | 14 | 2021 | 1003 | 1.130 |
Why?
|
Wireless Technology | 3 | 2017 | 102 | 1.130 |
Why?
|
Feasibility Studies | 10 | 2024 | 5315 | 1.130 |
Why?
|
Female | 228 | 2024 | 397187 | 1.130 |
Why?
|
Motivation | 7 | 2024 | 2020 | 1.120 |
Why?
|
Caregivers | 9 | 2023 | 2302 | 1.120 |
Why?
|
Humans | 305 | 2024 | 768171 | 1.090 |
Why?
|
Drug Monitoring | 7 | 2020 | 964 | 1.070 |
Why?
|
Hair | 5 | 2020 | 508 | 1.060 |
Why?
|
Cardiotocography | 2 | 2017 | 33 | 1.030 |
Why?
|
HIV-1 | 29 | 2024 | 6963 | 1.030 |
Why?
|
Young Adult | 79 | 2024 | 60066 | 1.010 |
Why?
|
Health Services Accessibility | 14 | 2024 | 5520 | 1.000 |
Why?
|
Sexual Behavior | 16 | 2024 | 2197 | 1.000 |
Why?
|
Glycerophospholipids | 3 | 2021 | 39 | 0.980 |
Why?
|
Monitoring, Ambulatory | 3 | 2020 | 358 | 0.970 |
Why?
|
Interviews as Topic | 17 | 2024 | 2741 | 0.890 |
Why?
|
Pregnancy Complications, Infectious | 12 | 2024 | 2185 | 0.870 |
Why?
|
Male | 170 | 2024 | 364731 | 0.870 |
Why?
|
Chemoprevention | 6 | 2024 | 327 | 0.870 |
Why?
|
Oral Health | 2 | 2020 | 493 | 0.870 |
Why?
|
Lamivudine | 2 | 2024 | 367 | 0.860 |
Why?
|
Unsafe Sex | 3 | 2021 | 239 | 0.810 |
Why?
|
RNA, Viral | 8 | 2017 | 2874 | 0.790 |
Why?
|
Disease Transmission, Infectious | 7 | 2024 | 560 | 0.790 |
Why?
|
Homosexuality, Male | 9 | 2022 | 1344 | 0.770 |
Why?
|
Adolescent | 61 | 2024 | 89169 | 0.760 |
Why?
|
Focus Groups | 5 | 2024 | 1460 | 0.690 |
Why?
|
Administration, Oral | 13 | 2024 | 4034 | 0.690 |
Why?
|
Self Care | 4 | 2019 | 799 | 0.670 |
Why?
|
Monitoring, Physiologic | 4 | 2021 | 1798 | 0.640 |
Why?
|
Vital Signs | 2 | 2021 | 146 | 0.640 |
Why?
|
Electronics | 4 | 2024 | 317 | 0.640 |
Why?
|
Insecticide-Treated Bednets | 1 | 2019 | 70 | 0.630 |
Why?
|
Peer Group | 1 | 2024 | 700 | 0.630 |
Why?
|
Health Knowledge, Attitudes, Practice | 12 | 2024 | 4055 | 0.610 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2018 | 102 | 0.610 |
Why?
|
Pilot Projects | 15 | 2024 | 8741 | 0.590 |
Why?
|
Pregnant Women | 2 | 2019 | 576 | 0.590 |
Why?
|
Dental Health Services | 1 | 2017 | 48 | 0.580 |
Why?
|
Nevirapine | 2 | 2018 | 273 | 0.580 |
Why?
|
CD4 Lymphocyte Count | 20 | 2020 | 2596 | 0.580 |
Why?
|
Pregnancy | 43 | 2024 | 30255 | 0.570 |
Why?
|
Deoxycytidine | 11 | 2015 | 887 | 0.560 |
Why?
|
Depression | 13 | 2020 | 8230 | 0.560 |
Why?
|
Postpartum Hemorrhage | 1 | 2021 | 275 | 0.560 |
Why?
|
Patient Preference | 3 | 2021 | 946 | 0.550 |
Why?
|
Safe Sex | 7 | 2024 | 144 | 0.540 |
Why?
|
Contact Tracing | 5 | 2023 | 275 | 0.530 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 590 | 0.500 |
Why?
|
Alcohol Drinking | 6 | 2023 | 4045 | 0.490 |
Why?
|
Maternal Health Services | 1 | 2021 | 472 | 0.490 |
Why?
|
Remote Sensing Technology | 1 | 2016 | 93 | 0.490 |
Why?
|
Fertilization | 4 | 2024 | 197 | 0.480 |
Why?
|
Condoms | 7 | 2024 | 337 | 0.470 |
Why?
|
Postpartum Period | 10 | 2023 | 1197 | 0.470 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3929 | 0.450 |
Why?
|
Rural Health Services | 2 | 2017 | 394 | 0.450 |
Why?
|
Child | 33 | 2024 | 80917 | 0.450 |
Why?
|
Professional-Patient Relations | 1 | 2019 | 724 | 0.440 |
Why?
|
Tuberculin Test | 3 | 2022 | 205 | 0.440 |
Why?
|
Gonorrhea | 3 | 2023 | 355 | 0.430 |
Why?
|
Delivery of Health Care | 7 | 2022 | 5367 | 0.430 |
Why?
|
Africa | 5 | 2021 | 725 | 0.430 |
Why?
|
Deception | 1 | 2014 | 100 | 0.430 |
Why?
|
Confidentiality | 3 | 2018 | 607 | 0.420 |
Why?
|
Contraception Behavior | 4 | 2020 | 186 | 0.420 |
Why?
|
Mass Screening | 7 | 2020 | 5458 | 0.420 |
Why?
|
Cesarean Section | 2 | 2021 | 1425 | 0.410 |
Why?
|
Developing Countries | 6 | 2022 | 2910 | 0.410 |
Why?
|
Self Report | 4 | 2019 | 3773 | 0.410 |
Why?
|
Oxazines | 2 | 2024 | 358 | 0.400 |
Why?
|
Mycobacterium tuberculosis | 2 | 2022 | 1930 | 0.400 |
Why?
|
Patient Care | 1 | 2017 | 629 | 0.390 |
Why?
|
Viremia | 5 | 2021 | 726 | 0.380 |
Why?
|
Infectious Disease Transmission, Vertical | 5 | 2021 | 1354 | 0.380 |
Why?
|
Prevalence | 19 | 2023 | 15869 | 0.380 |
Why?
|
Africa, Eastern | 5 | 2019 | 76 | 0.370 |
Why?
|
Telemetry | 1 | 2012 | 200 | 0.370 |
Why?
|
Middle Aged | 61 | 2024 | 223487 | 0.370 |
Why?
|
Resilience, Psychological | 1 | 2019 | 807 | 0.360 |
Why?
|
Prospective Studies | 41 | 2023 | 54924 | 0.360 |
Why?
|
Health Behavior | 2 | 2021 | 2650 | 0.350 |
Why?
|
Intention | 3 | 2020 | 347 | 0.350 |
Why?
|
Problem Solving | 1 | 2013 | 443 | 0.350 |
Why?
|
Kynurenine | 3 | 2017 | 142 | 0.350 |
Why?
|
HIV Integrase Inhibitors | 2 | 2022 | 165 | 0.340 |
Why?
|
Cohort Studies | 37 | 2024 | 41753 | 0.340 |
Why?
|
Longitudinal Studies | 17 | 2023 | 14783 | 0.340 |
Why?
|
Malaria | 1 | 2019 | 1249 | 0.330 |
Why?
|
Cross-Sectional Studies | 21 | 2022 | 26379 | 0.330 |
Why?
|
Patient Satisfaction | 3 | 2017 | 3490 | 0.330 |
Why?
|
Chlamydia Infections | 2 | 2023 | 365 | 0.320 |
Why?
|
Quality of Health Care | 3 | 2021 | 4310 | 0.320 |
Why?
|
Africa South of the Sahara | 7 | 2021 | 752 | 0.320 |
Why?
|
Pyridones | 2 | 2024 | 819 | 0.320 |
Why?
|
Pandemics | 5 | 2023 | 8747 | 0.320 |
Why?
|
Tryptophan | 3 | 2017 | 482 | 0.310 |
Why?
|
Drug Resistance, Viral | 7 | 2021 | 869 | 0.310 |
Why?
|
Serologic Tests | 3 | 2019 | 382 | 0.310 |
Why?
|
Pregnancy, Unplanned | 2 | 2019 | 85 | 0.300 |
Why?
|
Ambulatory Care Facilities | 5 | 2024 | 939 | 0.300 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7477 | 0.290 |
Why?
|
Technology | 3 | 2022 | 296 | 0.280 |
Why?
|
Mental Health | 3 | 2021 | 3275 | 0.280 |
Why?
|
Biomedical Research | 1 | 2023 | 3463 | 0.280 |
Why?
|
Privacy | 3 | 2019 | 233 | 0.280 |
Why?
|
Life Style | 1 | 2019 | 3932 | 0.280 |
Why?
|
Antitubercular Agents | 4 | 2024 | 1397 | 0.270 |
Why?
|
Primary Prevention | 1 | 2014 | 1188 | 0.270 |
Why?
|
Benzoxazines | 2 | 2018 | 320 | 0.270 |
Why?
|
Rural Health | 5 | 2015 | 302 | 0.270 |
Why?
|
Inflammation | 4 | 2021 | 10873 | 0.260 |
Why?
|
Iran | 3 | 2024 | 763 | 0.260 |
Why?
|
Medical Informatics | 1 | 2013 | 743 | 0.260 |
Why?
|
Women | 2 | 2021 | 225 | 0.260 |
Why?
|
Health Personnel | 3 | 2022 | 3384 | 0.250 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2024 | 10397 | 0.250 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2019 | 425 | 0.250 |
Why?
|
Self Efficacy | 2 | 2023 | 643 | 0.250 |
Why?
|
Contraceptive Agents | 3 | 2022 | 148 | 0.240 |
Why?
|
Epidemics | 2 | 2022 | 517 | 0.240 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2024 | 296 | 0.240 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2013 | 944 | 0.240 |
Why?
|
Smoking Cessation | 4 | 2020 | 2085 | 0.230 |
Why?
|
Diagnostic Tests, Routine | 2 | 2020 | 789 | 0.230 |
Why?
|
Clinical Competence | 1 | 2020 | 4858 | 0.230 |
Why?
|
Transportation | 3 | 2015 | 217 | 0.230 |
Why?
|
Biomedical Technology | 2 | 2017 | 210 | 0.230 |
Why?
|
Piperazines | 2 | 2024 | 2554 | 0.220 |
Why?
|
Postal Service | 2 | 2020 | 96 | 0.210 |
Why?
|
Hypertension | 2 | 2021 | 8616 | 0.210 |
Why?
|
Pain | 1 | 2017 | 5099 | 0.200 |
Why?
|
Data Collection | 2 | 2015 | 3326 | 0.200 |
Why?
|
Foot Bones | 1 | 2002 | 23 | 0.200 |
Why?
|
Chicago | 2 | 2020 | 255 | 0.200 |
Why?
|
Urban Population | 3 | 2020 | 2046 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 879 | 0.200 |
Why?
|
Alanine | 1 | 2024 | 614 | 0.190 |
Why?
|
Behavioral Sciences | 1 | 2021 | 29 | 0.190 |
Why?
|
Reproductive Behavior | 1 | 2021 | 27 | 0.180 |
Why?
|
Child Behavior | 2 | 2019 | 864 | 0.180 |
Why?
|
Retrospective Studies | 12 | 2023 | 81760 | 0.180 |
Why?
|
Parents | 1 | 2015 | 3595 | 0.180 |
Why?
|
Men | 1 | 2021 | 64 | 0.180 |
Why?
|
Hematuria | 1 | 2002 | 232 | 0.180 |
Why?
|
Interpersonal Relations | 5 | 2017 | 1434 | 0.180 |
Why?
|
Geographic Information Systems | 2 | 2013 | 283 | 0.180 |
Why?
|
Contraception | 2 | 2022 | 362 | 0.180 |
Why?
|
Syphilis | 1 | 2023 | 243 | 0.180 |
Why?
|
Program Evaluation | 2 | 2021 | 2507 | 0.180 |
Why?
|
Clinical Trials as Topic | 4 | 2019 | 8052 | 0.170 |
Why?
|
HIV Integrase | 1 | 2021 | 122 | 0.170 |
Why?
|
Primary Health Care | 4 | 2020 | 4746 | 0.170 |
Why?
|
Hospitals | 3 | 2023 | 3886 | 0.170 |
Why?
|
Interleukin-6 | 5 | 2021 | 3229 | 0.170 |
Why?
|
Attitude to Health | 3 | 2020 | 2025 | 0.170 |
Why?
|
Homosexuality | 1 | 2020 | 269 | 0.170 |
Why?
|
Zambia | 3 | 2020 | 273 | 0.170 |
Why?
|
Trust | 3 | 2019 | 532 | 0.170 |
Why?
|
Managed Care Programs | 1 | 2005 | 939 | 0.170 |
Why?
|
Blood Chemical Analysis | 2 | 2018 | 435 | 0.170 |
Why?
|
Medically Uninsured | 1 | 2005 | 840 | 0.170 |
Why?
|
Time Factors | 13 | 2021 | 40220 | 0.160 |
Why?
|
Socioeconomic Factors | 7 | 2020 | 7852 | 0.160 |
Why?
|
Researcher-Subject Relations | 1 | 2018 | 15 | 0.160 |
Why?
|
Awards and Prizes | 1 | 2023 | 365 | 0.160 |
Why?
|
Culicidae | 1 | 2019 | 111 | 0.160 |
Why?
|
Stomach | 1 | 2003 | 701 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 535 | 0.160 |
Why?
|
DNA Fingerprinting | 1 | 2018 | 114 | 0.150 |
Why?
|
Treatment Outcome | 20 | 2024 | 65379 | 0.150 |
Why?
|
Adolescent Behavior | 2 | 2019 | 1186 | 0.150 |
Why?
|
Stillbirth | 1 | 2021 | 381 | 0.150 |
Why?
|
Pleasure | 1 | 2018 | 41 | 0.150 |
Why?
|
Regression Analysis | 8 | 2015 | 6340 | 0.150 |
Why?
|
Osteomyelitis | 1 | 2002 | 408 | 0.150 |
Why?
|
Maternal Mortality | 1 | 2021 | 310 | 0.150 |
Why?
|
Leishmania | 1 | 1998 | 75 | 0.150 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2663 | 0.150 |
Why?
|
Odds Ratio | 7 | 2021 | 9669 | 0.150 |
Why?
|
World Health Organization | 3 | 2021 | 1328 | 0.140 |
Why?
|
Research Subjects | 1 | 2019 | 249 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2017 | 135 | 0.140 |
Why?
|
Smoking | 5 | 2020 | 9092 | 0.140 |
Why?
|
Public Health | 3 | 2021 | 2679 | 0.140 |
Why?
|
Developed Countries | 2 | 2010 | 451 | 0.140 |
Why?
|
Treatment Failure | 5 | 2024 | 2661 | 0.140 |
Why?
|
Poverty | 3 | 2023 | 2720 | 0.140 |
Why?
|
Drug Therapy, Combination | 6 | 2016 | 6316 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2018 | 2008 | 0.140 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 1998 | 137 | 0.140 |
Why?
|
Hospitalization | 4 | 2023 | 10840 | 0.140 |
Why?
|
AIDS Serodiagnosis | 1 | 2018 | 220 | 0.130 |
Why?
|
Self Administration | 1 | 2017 | 386 | 0.130 |
Why?
|
Checklist | 2 | 2021 | 840 | 0.130 |
Why?
|
Violence | 2 | 2012 | 936 | 0.130 |
Why?
|
Child, Preschool | 8 | 2022 | 42669 | 0.130 |
Why?
|
Antigens, Protozoan | 1 | 1998 | 315 | 0.130 |
Why?
|
Social Isolation | 1 | 2019 | 366 | 0.130 |
Why?
|
United States | 9 | 2023 | 73039 | 0.130 |
Why?
|
Gender Identity | 1 | 2021 | 770 | 0.130 |
Why?
|
Midwifery | 1 | 2017 | 131 | 0.120 |
Why?
|
Sexual Abstinence | 1 | 2015 | 17 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4861 | 0.120 |
Why?
|
Patient Dropouts | 1 | 2017 | 411 | 0.120 |
Why?
|
Biometry | 1 | 2018 | 570 | 0.120 |
Why?
|
Public Health Practice | 1 | 2017 | 221 | 0.120 |
Why?
|
Health Resources | 2 | 2018 | 950 | 0.120 |
Why?
|
House Calls | 1 | 2017 | 171 | 0.120 |
Why?
|
National Health Programs | 2 | 2009 | 442 | 0.120 |
Why?
|
Logistic Models | 5 | 2021 | 13290 | 0.120 |
Why?
|
Diabetic Retinopathy | 1 | 2024 | 1300 | 0.120 |
Why?
|
Obstetric Labor Complications | 1 | 2017 | 244 | 0.120 |
Why?
|
Heart Rate, Fetal | 1 | 2015 | 77 | 0.120 |
Why?
|
Ischemia | 1 | 2003 | 1900 | 0.120 |
Why?
|
Saliva | 1 | 2019 | 853 | 0.120 |
Why?
|
Health Services Research | 2 | 2018 | 1815 | 0.110 |
Why?
|
Risk Factors | 16 | 2023 | 74944 | 0.110 |
Why?
|
Labor, Obstetric | 1 | 2017 | 323 | 0.110 |
Why?
|
Soil | 1 | 2014 | 120 | 0.110 |
Why?
|
Delivery, Obstetric | 1 | 2021 | 954 | 0.110 |
Why?
|
Helminthiasis | 1 | 2014 | 81 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2018 | 620 | 0.110 |
Why?
|
Interview, Psychological | 1 | 2016 | 810 | 0.110 |
Why?
|
Dangerous Behavior | 1 | 2013 | 65 | 0.110 |
Why?
|
Self Disclosure | 1 | 2014 | 248 | 0.110 |
Why?
|
Mental Disorders | 1 | 2013 | 6873 | 0.110 |
Why?
|
Markov Chains | 1 | 2016 | 979 | 0.100 |
Why?
|
Recombination, Genetic | 1 | 2017 | 1525 | 0.100 |
Why?
|
Medicine, African Traditional | 1 | 2013 | 31 | 0.100 |
Why?
|
Informed Consent | 1 | 2019 | 1010 | 0.100 |
Why?
|
Survival Analysis | 3 | 2020 | 10099 | 0.100 |
Why?
|
Drug Utilization | 1 | 2018 | 1189 | 0.100 |
Why?
|
HIV Antibodies | 1 | 2019 | 1341 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2015 | 20225 | 0.100 |
Why?
|
Boston | 2 | 2022 | 9374 | 0.100 |
Why?
|
Electrical Equipment and Supplies | 1 | 2012 | 28 | 0.100 |
Why?
|
San Francisco | 1 | 2012 | 166 | 0.100 |
Why?
|
Puerperal Disorders | 1 | 2014 | 304 | 0.100 |
Why?
|
Medicaid | 1 | 2005 | 2840 | 0.100 |
Why?
|
Epitopes | 1 | 1998 | 2527 | 0.100 |
Why?
|
Incidence | 9 | 2022 | 21538 | 0.100 |
Why?
|
Weight Loss | 1 | 2003 | 2721 | 0.100 |
Why?
|
Health Promotion | 2 | 2021 | 2210 | 0.100 |
Why?
|
Heterosexuality | 3 | 2021 | 309 | 0.090 |
Why?
|
Risk | 2 | 2021 | 9613 | 0.090 |
Why?
|
Home Care Services | 1 | 2018 | 659 | 0.090 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2017 | 620 | 0.090 |
Why?
|
Referral and Consultation | 2 | 2021 | 3620 | 0.090 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2010 | 39 | 0.090 |
Why?
|
Psychotherapy, Group | 1 | 2014 | 417 | 0.090 |
Why?
|
Obstetrics | 1 | 2017 | 681 | 0.090 |
Why?
|
Health Communication | 1 | 2013 | 216 | 0.090 |
Why?
|
Drug Implants | 2 | 2024 | 230 | 0.090 |
Why?
|
Reimbursement Mechanisms | 1 | 2015 | 670 | 0.080 |
Why?
|
Models, Statistical | 3 | 2018 | 5107 | 0.080 |
Why?
|
Risk-Taking | 4 | 2020 | 1023 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2014 | 800 | 0.080 |
Why?
|
Intention to Treat Analysis | 2 | 2022 | 416 | 0.080 |
Why?
|
Mass Vaccination | 1 | 2010 | 111 | 0.080 |
Why?
|
China | 6 | 2015 | 2395 | 0.080 |
Why?
|
Breast Feeding | 2 | 2020 | 1363 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10763 | 0.080 |
Why?
|
Research Design | 3 | 2019 | 6209 | 0.080 |
Why?
|
Tobacco Use Disorder | 1 | 2014 | 708 | 0.080 |
Why?
|
Telephone | 1 | 2012 | 630 | 0.080 |
Why?
|
HIV Reverse Transcriptase | 2 | 2009 | 214 | 0.070 |
Why?
|
Health Policy | 1 | 2020 | 2697 | 0.070 |
Why?
|
Suicidal Ideation | 1 | 2018 | 1462 | 0.070 |
Why?
|
Forecasting | 1 | 2017 | 2945 | 0.070 |
Why?
|
Postnatal Care | 2 | 2020 | 273 | 0.070 |
Why?
|
Alkynes | 2 | 2018 | 326 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2740 | 0.070 |
Why?
|
Age Factors | 4 | 2019 | 18415 | 0.070 |
Why?
|
Cyclopropanes | 2 | 2018 | 436 | 0.070 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 747 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12077 | 0.070 |
Why?
|
Health Plan Implementation | 3 | 2020 | 338 | 0.070 |
Why?
|
Plasma | 2 | 2024 | 585 | 0.070 |
Why?
|
Genotype | 2 | 2018 | 13045 | 0.070 |
Why?
|
Abdominal Pain | 2 | 2003 | 1070 | 0.070 |
Why?
|
Reward | 1 | 2013 | 981 | 0.060 |
Why?
|
Malnutrition | 1 | 2012 | 632 | 0.060 |
Why?
|
Cross-Over Studies | 2 | 2024 | 2107 | 0.060 |
Why?
|
India | 2 | 2024 | 2334 | 0.060 |
Why?
|
Point-of-Care Systems | 2 | 2024 | 1238 | 0.060 |
Why?
|
Deoxyadenosines | 1 | 2024 | 27 | 0.060 |
Why?
|
Disease Progression | 2 | 2021 | 13668 | 0.060 |
Why?
|
Information Dissemination | 1 | 2013 | 1143 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2012 | 4640 | 0.060 |
Why?
|
Research | 1 | 2013 | 1979 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2016 | 12466 | 0.060 |
Why?
|
Papillomavirus Vaccines | 1 | 2010 | 497 | 0.060 |
Why?
|
Sampling Studies | 1 | 2005 | 615 | 0.060 |
Why?
|
Communication | 1 | 2018 | 3905 | 0.060 |
Why?
|
T-Lymphocytes | 2 | 2017 | 10266 | 0.050 |
Why?
|
Celiac Artery | 1 | 2003 | 65 | 0.050 |
Why?
|
Stomach Ulcer | 1 | 2003 | 118 | 0.050 |
Why?
|
Preconception Care | 1 | 2024 | 143 | 0.050 |
Why?
|
Aged | 10 | 2022 | 171502 | 0.050 |
Why?
|
Mesenteric Arteries | 1 | 2003 | 178 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2020 | 1854 | 0.050 |
Why?
|
Fundus Oculi | 1 | 2024 | 560 | 0.050 |
Why?
|
Anorexia | 1 | 2003 | 153 | 0.050 |
Why?
|
Internship and Residency | 1 | 2023 | 5953 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2024 | 14729 | 0.050 |
Why?
|
Drug Combinations | 3 | 2013 | 2089 | 0.050 |
Why?
|
Latin America | 2 | 2015 | 416 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2016 | 4887 | 0.050 |
Why?
|
Leukocytosis | 1 | 2003 | 251 | 0.050 |
Why?
|
Radiography | 2 | 2003 | 6986 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2024 | 3573 | 0.050 |
Why?
|
Africa, Northern | 1 | 2021 | 86 | 0.050 |
Why?
|
Gastritis | 1 | 2003 | 199 | 0.050 |
Why?
|
Cameroon | 1 | 2021 | 79 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2014 | 4415 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2002 | 239 | 0.050 |
Why?
|
Probability | 2 | 2018 | 2479 | 0.050 |
Why?
|
Middle East | 1 | 2021 | 233 | 0.040 |
Why?
|
Polypharmacy | 1 | 2023 | 307 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2015 | 2666 | 0.040 |
Why?
|
Placebos | 2 | 2015 | 1667 | 0.040 |
Why?
|
Health Surveys | 3 | 2020 | 4057 | 0.040 |
Why?
|
Atherosclerosis | 1 | 2016 | 3433 | 0.040 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2003 | 282 | 0.040 |
Why?
|
Southeastern United States | 1 | 2019 | 93 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2024 | 1026 | 0.040 |
Why?
|
Nitriles | 1 | 2024 | 980 | 0.040 |
Why?
|
Isoniazid | 1 | 2020 | 288 | 0.040 |
Why?
|
New York City | 1 | 2021 | 737 | 0.040 |
Why?
|
Protozoan Vaccines | 1 | 1998 | 13 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 13091 | 0.040 |
Why?
|
Papillomavirus Infections | 1 | 2010 | 1640 | 0.040 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2010 | 2043 | 0.040 |
Why?
|
Vietnam | 1 | 2019 | 415 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2005 | 2434 | 0.040 |
Why?
|
Pulmonary Emphysema | 1 | 2003 | 689 | 0.040 |
Why?
|
Cities | 1 | 2020 | 543 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11930 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2003 | 13013 | 0.040 |
Why?
|
Lymphocyte Activation | 2 | 2018 | 5505 | 0.040 |
Why?
|
Communicable Disease Control | 1 | 2023 | 857 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2003 | 804 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5536 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1599 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 640 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 1157 | 0.030 |
Why?
|
HLA-B Antigens | 1 | 2017 | 330 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1216 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12543 | 0.030 |
Why?
|
Hypotension | 1 | 2002 | 888 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2515 | 0.030 |
Why?
|
Quality of Life | 2 | 2015 | 13490 | 0.030 |
Why?
|
Prenatal Care | 2 | 2014 | 1162 | 0.030 |
Why?
|
Family Planning Services | 1 | 2018 | 279 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2121 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15453 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10632 | 0.030 |
Why?
|
Schools | 1 | 2023 | 1498 | 0.030 |
Why?
|
Behavior Therapy | 1 | 2020 | 886 | 0.030 |
Why?
|
Fever | 1 | 2002 | 1614 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2020 | 718 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1725 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15949 | 0.030 |
Why?
|
Infant, Newborn | 3 | 2023 | 26421 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22290 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2018 | 942 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 24318 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2017 | 664 | 0.030 |
Why?
|
Contraceptive Agents, Female | 1 | 2015 | 123 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1557 | 0.030 |
Why?
|
Genome, Viral | 1 | 2017 | 674 | 0.030 |
Why?
|
Retina | 1 | 2024 | 2662 | 0.030 |
Why?
|
Comorbidity | 2 | 2021 | 10590 | 0.030 |
Why?
|
Fertility | 1 | 2018 | 771 | 0.030 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 117 | 0.030 |
Why?
|
Prognosis | 3 | 2019 | 30009 | 0.030 |
Why?
|
Dyspnea | 1 | 2021 | 1352 | 0.030 |
Why?
|
Internal-External Control | 1 | 2014 | 348 | 0.030 |
Why?
|
Databases, Factual | 2 | 2024 | 8080 | 0.030 |
Why?
|
Argentina | 1 | 2013 | 249 | 0.030 |
Why?
|
Models, Psychological | 1 | 2016 | 825 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 15662 | 0.030 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2012 | 62 | 0.020 |
Why?
|
Organophosphorus Compounds | 1 | 2013 | 211 | 0.020 |
Why?
|
Infant | 3 | 2023 | 36535 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2021 | 1546 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 1001 | 0.020 |
Why?
|
Triage | 1 | 2019 | 997 | 0.020 |
Why?
|
Social Behavior | 1 | 2018 | 1147 | 0.020 |
Why?
|
Body Weight | 2 | 2016 | 4627 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2023 | 2972 | 0.020 |
Why?
|
Cytokines | 2 | 2015 | 7452 | 0.020 |
Why?
|
ROC Curve | 1 | 2019 | 3628 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39354 | 0.020 |
Why?
|
Ethics, Research | 1 | 2013 | 178 | 0.020 |
Why?
|
Stereotyping | 1 | 2013 | 241 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2019 | 2359 | 0.020 |
Why?
|
Perception | 1 | 2017 | 1209 | 0.020 |
Why?
|
Spouse Abuse | 1 | 2012 | 182 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2337 | 0.020 |
Why?
|
Creatinine | 1 | 2016 | 1918 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2732 | 0.020 |
Why?
|
Animals | 2 | 2019 | 169285 | 0.020 |
Why?
|
Biopsy | 1 | 2002 | 6792 | 0.020 |
Why?
|
Mutation | 4 | 2021 | 30237 | 0.020 |
Why?
|
Peru | 1 | 2013 | 890 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2002 | 2171 | 0.020 |
Why?
|
Brazil | 1 | 2013 | 1250 | 0.020 |
Why?
|
California | 1 | 2012 | 1438 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 951 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1254 | 0.020 |
Why?
|
Local Government | 1 | 2007 | 83 | 0.020 |
Why?
|
Travel | 1 | 2013 | 805 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 2029 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 714 | 0.020 |
Why?
|
Health Literacy | 1 | 2012 | 466 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4786 | 0.020 |
Why?
|
Plasma Exchange | 1 | 2007 | 159 | 0.020 |
Why?
|
Algorithms | 2 | 2023 | 14164 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 7073 | 0.020 |
Why?
|
Oximetry | 1 | 1989 | 462 | 0.020 |
Why?
|
Government Programs | 1 | 2007 | 278 | 0.020 |
Why?
|
Social Class | 1 | 2014 | 2008 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 3670 | 0.020 |
Why?
|
Expert Systems | 1 | 2005 | 79 | 0.010 |
Why?
|
Antigens, CD | 1 | 2015 | 4035 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4648 | 0.010 |
Why?
|
Financing, Government | 1 | 2007 | 473 | 0.010 |
Why?
|
Nutritional Status | 1 | 2012 | 1628 | 0.010 |
Why?
|
Health Education | 1 | 2010 | 1059 | 0.010 |
Why?
|
Health Care Costs | 1 | 2017 | 3239 | 0.010 |
Why?
|
Lung | 1 | 2002 | 10101 | 0.010 |
Why?
|
Decision Trees | 1 | 2005 | 508 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5891 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6525 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2013 | 2783 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2007 | 1309 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2012 | 3072 | 0.010 |
Why?
|
Drug Costs | 1 | 2007 | 1195 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3269 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16044 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2007 | 6229 | 0.010 |
Why?
|
Disease Outbreaks | 1 | 2007 | 1761 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 13053 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2018 | 59626 | 0.010 |
Why?
|
Phenotype | 1 | 2005 | 16726 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1627 | 0.000 |
Why?
|